Enhance your practice with CMEand tools that focus on the managementand treatment of patients with cancer.
DLL3 Expression in GEP-NECs: A Marker of Poor Differentiation and Emerging Therapeutic Target
Biomarker Breakthroughs: A Look at What’s Next for Kidney Cancer Care
Ryan Quigley
David F. McDermott, MD
Optimizing Nivolumab in NSCLC: Implications for Cost, Access, and Outcomes
Aline Fares, MD
Uncovering Unmet Needs in Squamous Cell Carcinoma of the Anal Canal Care
Richard Kim, MD
One Year or Two? DANTE Trial Explores Immunotherapy Duration in Metastatic Melanoma
New Frontiers in the Imaging and Treatment of Advanced Prostate Cancer
Wayne Kuang, MD
William Oh, MD
Unpacking the Logistics of At-Home Subcutaneous Cancer Immunotherapy Delivery
Jorge Nieva, MD
Early-Onset Endometrial Cancer: Bridging the Gap Between Age and Outcome
First-line Chemotherapy Options in Metastatic PDAC
Eileen O’Reilly, MD
Case Consult: Adverse Effect Monitoring, Management, and Mitigation During Targeted Therapy for BRAF-Mutant mCRC
Fortunato Ciardiello, MD, PhD
Jenny Seligmann, MBChB, PhD
Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond
Mastering Mutation-Driven mCRC: From Testing to Targeted Therapy
Scott Kopetz, MD, PhD
Cathy Eng, MD, FACP
Liquid Biopsy for Colorectal Cancer Screening: Benefits and Barriers
Charles Turck, PharmD, BCPS, BCCCP
Brennan Spiegel, MD, MSHS
Assessing Efficacy and Cost of Blood-Based Tests for Colorectal Cancer
Samuel Muench, MD
Studying Carboplatin-Paclitaxel + Retifanlimab for Squamous Cell Carcinoma of the Anal Canal
Bringing Cancer Care Home: How Subcutaneous Immunotherapy Can Help Ease the Burden
Debunking CAR T-Cell Myths: The Realities of Patient Selection, Safety, and Access
Matthew Lunning, DO, FACP
Androgen Receptor Emerges as a Marker of Differentiation in Endometrial Cancer
Investigating At-Home Subcutaneous Atezolizumab for NSCLC: An Ongoing Study
Overall Survival with Neoadjuvant Therapy in HNSCC: Examining Real-World Data
Vanessa Helou, MD
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.